Navigation Links
New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures

percent. The non-serious rash rate was 2 percent for Lamictal XR and <1 percent for placebo. No serious rash was reported.

ABOUT THE COMPASS STUDY

The second trial (COMPASS) compared the pharmacokinetics of twice daily, immediate release Lamictal to once daily Lamictal XR in patients thirteen years of age and older with epilepsy. The open label, conversion study consisted of a 2 week base line phase with Lamictal immediate release, a 2 week treatment phase with Lamictal XR and a 1 week treatment phase with Lamictal immediate release. The study outcomes included lamotrigine pharmacokinetics upon conversion and seizure frequency during each treatment phase.

Results showed the steady state trough concentrations for Lamictal XR were equivalent to or higher than those of Lamictal immediate release depending on concomitant AED. In addition, there was no change in the median weekly seizure frequency among the groups.

ABOUT EPILEPSY

Epilepsy, defined by recurrent unprovoked seizures, is a change in sensation, awareness, or behavior brought about by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the electrical disturbance that produces seizures. Generalized seizures are seizures that involve the entire brain from the outset. Partial seizures, which are more common, involve a restricted area of the brain. In approximately 70 percent of cases, the cause of epilepsy is unknown. According to the Epilepsy Foundation, more than three million Americans of all ages are living with epilepsy.

ABOUT LAMICTAL IMMEDIATE RELEASE (IR) FORMULATION

Lamictal is indicated 1) as adjunctive therapy for partial seizures, primary generalized tonic-clonic seizures, and the generalized seizures of Lennox-Gastaut syndrome in adults and pediatric patients as young as 2 years and 2) for conversion to monotherapy in adults with partial seizures taking carbamazepine, p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:7/29/2015)... July 29, 2015  Shareholder rights law firm ... certain officers and directors of AMAG Pharmaceuticals, Inc. ... AMAG Pharmaceuticals operates as a specialty pharmaceutical company ... supportive care.  The company markets Makena, a hydroxyprogesterone ... birth in women with a singleton pregnancy. ...
(Date:7/29/2015)... LOVELAND, Colo., July 29, 2015 Heska Corporation ... "Company"), a provider of advanced veterinary diagnostic and other ... second quarter ended June 30, 2015. Second ... from Operations was up nearly 100% to $1.829 million, from ... 29% to $10.1 million, from $7.8 million. , Core ...
(Date:7/29/2015)... The Judicial Panel on Multidistrict Litigation (JPML) will hear ... vena cava (IVC) Filter lawsuits filed against C.R. Bard.  ... been centralized by the JPML. "IVC filters ... a pulmonary embolism. The filters are designed to prevent ... Bard and Cook involve incidents of retrievable IVC filters ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of AMAG Pharmaceuticals, Inc. (AMAG) on Behalf of Shareholders 2Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8IVC filter litigation continues; law firm provides free information to IVC filter patients 2
... leading biopharmaceutical company committed to the development of new ... key sets of Vimpat® (lacosamide) C-V data at the ... in Baltimore, Md., December 2-6.  "At ... lives of people living with epilepsy," said Dr. James ...
... 2011   Octapharma USA announced that octagam ® ... for purchase. The U.S. Food and Drug Administration (FDA) ... ® 5% , a